Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)
Clinical trial NCT04758975 · RECRUITING
Trial details
- NCT number
- NCT04758975
- Sponsor
- Paolo Ghia
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-19
- Primary completion
- 2024-12-31
- Enrollment
- 55
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.